(Q34393961)

1 August 2017

1 reference

title

How is androgen-dependent metastatic prostate cancer best treated? (English)

1 reference

1 August 2017

1 reference

Robson M

1

1 reference

1 August 2017

Dawson N

series ordinal

2

1 reference

1 August 2017

publication date

1 June 1996

1 reference

Hematology / Oncology Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

10

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

727-747

1 reference

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Carcinoma of the prostate; a study of the postmortem findings in 176 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Control of prostate cancer with radiotherapy: long-term results.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

The dedifferentiation of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

II. The Question of Castration for Enlarged Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Patients' choice of treatment in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Suramin and prostate cancer: where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prostate cancer. Primary hormonal treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prostate Specific Antigen and Prostatic Acid Phosphatase for Monitoring Therapy of Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Metastases from cancer of the prostate; autopsy and roentgenological findings

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Combination treatment in M1 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Basis for hormonal management of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Treatment of advanced cancer of prostate with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Medical castration of males with megestrol acetate and small doses of diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Early Prostate Cancer: The National Results of Radiation Treatment from the Patterns of Care and Radiation Therapy Oncology Group Studies With Prospects for Improvement with Conformal Radiation and Adjuvant Androgen Deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Pre-treatment testosterone levels: significance in androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Carcinoma of prostate correlation between radiologic quantitation of metastases and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Spread of prostatic cancer to bone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Medical castration using megestrol acetate and minidose estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Predictive initial parameters for response of stage D prostate cancer to treatment with the luteinizing hormone-releasing hormone agonist goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Activation of programmed cell death in the rat ventral prostate after castration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Indications for use of ketoconazole in management of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Flutamide as primary treatment for metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Flutamide therapy for advanced prostatic cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Ketoconazole and liarozole in the treatment of advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Ketoconazole as Primary Treatment of Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

National Patterns of Prostate Cancer Treatment by Radical Prostatectomy: Results of a Survey by the American College of Surgeons Commission on Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Can Radical Prostatectomy Alter the Progression of Poorly Differentiated Prostate Cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Impact of Radical Prostatectomy in the Management of Clinically Localized Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urolo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Nilutamide pneumonitis: a report on eight patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Long-term experience with flutamide in patients with prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Carcinoma of the prostate with soft tissue or non-regional lymphatic metastases at the time of diagnosis: a review of 47 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Isolation and properties of the FSH and LH-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Experience with Flutamide in Previously Untreated Patients With Advanced Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

The importance of prognostic factors in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Antiandrogenic agents as monotherapy in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Ketoconazole: A Novel and Rapid Treatment for Advanced Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Ketoconazole therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Ketoconazole therapy for advanced prostatic cancer: feasibility and treatment results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Factors in the prognosis of carcinoma of the prostate: a cooperative study. The Veterans Administration Cooperative Urological Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

II. The Present Position of the Surgery of the Hypertrophied Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Cancer of the prostate. Do younger men have a poorer survival rate?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Fatal and nonfatal hepatotoxicity associated with flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970364-6

7 January 2021

10.1016/S0889-8588(05)70364-6

Identifiers

DOI

1 reference

1 August 2017

1 reference